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Table 3. Kidney Biopsy Findings of Patients with Monoclonal Gammopathy.
Patient
No.
Pattern
of Injury
%Globally
Sclerosed Glomerull
%Crescent %Interstitial
Fibrosis
IF Microscopy EM
1 MPGN 5.4% 2.7% 20.0% C3 2 + (CW) Endotheliocyte injuried，subendothelial
expansion with fluffy material
2 MPGN 55.0% 0.0% 25.0% C3 2 + (CW and MES) electron-dense deposits in MES and SU
3 MPGN 17.6% 0.0% 20.0% C3 2 + (CW and MES) electron-dense deposits in MES
4 MPGN 0.0% 0.0% 25.0% C3 2 + (CW and MES) subendothelial expansion with fluffy material
5 MPGN 14.9% 3.7% 10.0% C3 2 + (CW) electron-dense deposits in MES and SU
6 MPGN 9.1% 0.0% 5.0% C3 2 + (CW and MES) electron-dense deposits in MES, SU and SE
7 MPGN 28.6% 0.0% 4.0%% C3 3 + (CW and MES)/IgG, IgM (trace) electron-dense deposits in MES, SU
MPGN Z membranoproliferative glomerulonephritis; CW Z capillary wall; MES Z mesangial; SE Z subepithelial; SU Z subendothelial.
S62 Other Specific NephropathiesConclusion: Monoclonal gammopathy was a predominant cause of
C3 GN in the older patients. Pattern of pathological injury was membra-
noproliferative. Immunodepressive therapy may be effective,
but the key point of therapy should be targeting monoclonal
gammopathy.http://dx.doi.org/10.1016/j.hkjn.2015.09.0100066
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Background: Higher glomerular PLA2R-antigen deposit (GAg) rates
compared with serum phospholipase A2 receptor-antibody (SAb) positive
rates were reported. However, the exact roles played by these two bio-
markers remain unknown.
Methods: A total of 572 patients diagnosed with IMN were included. Both SAb
and GAg were detected. Fifty-two IMN patients received repeat renal biopsy
were included.
Results: 572 patients, 401 (70.1%) were SAb positive (SAb+) while 171
(29.9%) were SAb negative (SAb-). In SAb+ patients, the glomerular
PLA2R-antigen deposition (GAg+) was observed in 99.1% (397/401). Inter-
estingly, the GAg+ was observed in 68.4% (117/171) Sab patients. Pa-
tients with SAb manifested more severe proteinuria (3.9 g/24 hours
vs. 2.8 g/24 hours, P < 0.001) and lower eGFR (104 ml/min/1.73 m2
vs. 110 ml/min/1.73 m2, P Z 0.002) than patients without SAb. Further
comparison between SAb+/GAg+ and SAb-/GAg+ showed a similar profile.
Patients with SAb+/GAg+ also showed lower chance of proteinuria
remission and higher chance of renal function decline in the follow up
when compared to patients with SAb-/GAg+. Changes of SAb and
GAg were observed in patients with repeat renal biopsy, in 11 patients
the SAb+ turned into SAb-, among them 1 patient failed to achieve
remission, 7 patients achieved remission and 4 remitted during the in-
terval but relapsed at the time of repeat biopsy. While the GAg+
turned into GAg- in only 3 patients, all achieved remission at the repeat
biopsy. The proportion of GAg disappearance was lower than SAb
(P Z 0.016).
Conclusion: The GAg deposit can be detected in a large proportion of SAb
negative patients, which can be explained by the lag of GAg disappearance
in the follow up. SAb was more tightly correlated to disease activity, treat-
ment response and prognosis than GAg. We recommend adopting GAg depo-
sit detection as a supplement to SAb in IMN diagnosis and continuing to
monitor SAb during follow-up.http://dx.doi.org/10.1016/j.hkjn.2015.09.0110074
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Background: Preeclampsia (PE) is a life-threatening hypertensive disorder of
pregnancy. Soluble fms-like tyrosine kinase 1 (sFlt-1) is elevated and known
to contribute to PE. However, molecular basis underlying its up-regulation in
PE remain unclear.
Methods and Results: By using immunohistochemistry and western blot, we
demonstrated hypoxia inducible factor-1a (HIF-1a), an important transcrip-
tional factor, andU2 small nuclear ribonucleoprotein auxiliary factor 65-kilodal-
ton subunit (U2AF65), a key factor involved in alternative splicing, are
significantly increased in the placental tissue fromPEpatients.Using two animal
models of PE including angiotensin II type 1 receptor agonistic autoantibody
(AT1-AA) and LIGHT (a TNF-a superfamily member)-induced PE mouse model
coupled with in vivo nanoliposome-delivery system to specifically knockdown
HIF-1a and U2AF65, we found that knockdown of HIF-1a or U2AF65 siRNA signif-
icantly attenuated AT1-AA-induced hypertension (HIF-1a siRNA: 137 4mmHg;
U2AF65 siRNA: 140 5 mmHg vs. AT1-AA group 164 3 mmHg, p < 0.05), pro-
teinuria (HIF-1a siRNA: 41.6 3.2 mg/mg, U2AF65 siRNA: 34.9 5.3 mg/mg vs.
AT1-AA group 85.9 4.8 mg albumin/mg creatinine, p < 0.05) and circulating
sFlt-1 level. Similarly, we found thatHIF-1a andU2AF65 knockdown significantly
reduced sFlt-1 levels, hypertension and proteinuria in LIGHT-infused pregnant
mice. Finally, using splice-specific PCR assay, we found that knockdown HIF-
1a significantly reduced total Flt-1 mRNA level in the placentas of both AT1-AA
and LIGHT-infused pregnant mice but no effect on the ratio of sFlt-1/ Flt-1. In
contrast, U2AF65 knock down significantly reduced the ratio of sFlt-1/ Flt-1
without an effect on total Flt-1 mRNA level in these two PE mouse models.
Conclusion: Overall, we have revealed two molecular basis underlying sFlt-1
inductions in PE: (1) elevated HIF-1a directly increases sFlt-1 levels under
transcriptional levels; (2) elevated U2AF65 enhances alternative splicing to
increase sFlt-1 levels.http://dx.doi.org/10.1016/j.hkjn.2015.09.0120078
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Objective: Long non-coding RNAs (lncRNAs) exert pathophysiologic functions in
many diseases. By using RNA sequencing,we recently found that lncRNA_5318 is
